It has been a quiet period for Fibrocell Science Inc.(OTC:FCSC) ever since the FDA Approval announcement for one of its products back in June. A quiet period, during which a serious decline in the stock price took place. A period, which ended last Wednesday. 
Last Wednesday, interested parties got the chance to hear from the company again. An announcement came out, explaining that Fibrocell Science is to raise $22 million in a private placement. No longer quiet, yet obviously not the right catalyst that could reverse the negative price trend. In fact, the last one from June mentioned above could not do that, either. It, however, managed to attract additional attention as an all-time high in terms of trading volume was reached that day.
Last Friday was a different story. Trading activity reached 645k shares exchanging hands, making up for another 5% decline in the stock price, the session closing at $0.51 per share. Just 3 months ago, sessions would close at $1.31 per share. So, the question is – what would it take for this stock to change its direction?
Now, the FDA approval for the company’s product is certainly a milestone not to go overlooked, but it seems that current and potential shareholders are looking for something more. Not exactly surprising, considering the balance sheet. The last quarterly statement to come was the 10-Q covering the first 3 months of the year. It includes figures like a net loss of $17 million for the specified period alone. A number, 4 times bigger than the total current assets of the company as at March, 31st. [BANNER]
With the above in mind, it is still uncertainty that prevails for FCSC on the stock market. While a reverse is a possibility, a share price decline is also possible. In terms, caution should be applied when considering an investment in this company.
